Insilico Medicine introduced LEGION, an advanced artificial intelligence platform designed to exhaustively explore chemical space for novel drug molecules. LEGION aims both to discover promising therapeutic candidates and preempt competitors from patenting chemically similar compounds, providing a strategic double advantage. The system was applied to the inflammatory target NLRP3, with plans to submit an IND to begin clinical trials of a potential Parkinson’s disease therapy. This innovative approach exemplifies AI's growing role in accelerating and securing pharmaceutical R&D.